Some thought this day would never arrive. After two prior failed attempts, Dynavax Technologies (NASDAQ: DVAX) finally won approval for hepatitis B vaccine Heplisav-B.
The company announced the great news after the market closed on Thursday. Dynavax stock jumped on Friday, adding to year-to-date gains of close to 470%. But with shares already soaring so much this year, is it too late to buy Dynavax stock now that Heplisav-B has won approval? I don’t think so.
Image source: Getty Images.